Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Intuitive Surgical stock: Q3 growth meets $450 million charge

Antitrust case Company update Earnings report AI-generated analysis

πŸ“ˆ Intuitive Surgical revenue surged 22% to $3.05 billion in Q3, driven by strong performance across da Vinci and Ion systems.

πŸ”§ The company placed 546 da Vinci systems in the quarter, including 315 units of the newer da Vinci 5 model.

βš–οΈ GAAP earnings were impacted by a $450 million pretax charge related to a proposed antitrust litigation settlement.

πŸ“Š Non-GAAP net income increased to $1.05 billion, reflecting underlying business growth despite the legal expense.

πŸš€ Worldwide da Vinci procedure volume is expected to grow 14% to 15% in 2026, with performance near the midpoint.

πŸ’° Instruments and accessories revenue jumped 18% to $1.80 billion as customers utilized more consumables.

πŸ₯ The installed base expanded to 12,094 da Vinci systems and 1,152 Ion systems by the end of September.

πŸ“‰ Operating expenses are forecasted to grow 11% to 13% for the full year under current tariff conditions.

πŸ‘¨β€πŸ’Ό CEO Dave Rosa noted customers performed over 10,000 procedures per day on average during the third quarter.

πŸ“‰ The proposed antitrust settlement requires preliminary and final court approval before becoming effective.

Bullish Signals
  • Revenue grew 22% year-over-year to $3.05 billion, demonstrating strong top-line momentum driven by system adoption and procedure volume.
  • Non-GAAP net income rose to $1.05 billion, indicating robust underlying profitability despite the one-time legal charge.
  • The company placed 546 da Vinci systems in Q3, including a significant number of the newer da Vinci 5 models, expanding its installed base.
  • Ion procedures climbed 31% year-over-year, highlighting successful diversification and growth in the company's second robotic platform.
  • Instruments and accessories revenue increased 18% to $1.80 billion, reflecting high utilization rates and recurring revenue streams.
  • Management expects worldwide da Vinci procedure growth of 14% to 15% for 2026, with performance anticipated near the midpoint of that range.
Risk Factors
  • GAAP net income fell to $523 million due to a $450 million pretax charge tied to a proposed antitrust litigation settlement.
  • The proposed antitrust settlement includes injunctive relief and payments but remains subject to preliminary and final court approval.
  • Operating expenses are forecasted to grow 11% to 13% for the full year, which may compress margins if procedure growth does not keep pace.
Full Analysis
Intuitive Surgical reported robust third-quarter financial performance driven by significant growth in both system placements and procedure volumes. Revenue for the quarter ended September 30 reached $3.05 billion, representing a 22% year-over-year increase from the prior period. This growth was fueled by a 14% rise in da Vinci procedures and a substantial 31% increase in Ion procedures, alongside an 18% surge in instruments and accessories revenue. Despite strong operational metrics, GAAP net income declined to $523 million due to a $450 million pretax charge associated with a proposed antitrust litigation settlement. On a non-GAAP basis, however, the company demonstrated underlying profitability growth, with net income rising to $1.05 billion. The installed base expanded significantly, reaching 12,094 da Vinci systems and 1,152 Ion systems, reflecting continued market adoption. Management provided forward-looking guidance expecting worldwide da Vinci procedure growth between 14% and 15% for the full year 2026. The company also forecasts a non-GAAP gross margin of 68.7% to 69.3% and operating expense growth of 11% to 13%, contingent on current tariff conditions remaining in force through year-end. CEO Dave Rosa highlighted high daily procedure volumes, averaging over 10,000 per day during the quarter.